Covid vaccine race lights fire under GSK boss as RSV battle intensifies
GSK Plc is planning to launch a Covid shot that comes almost two years after Pfizer Inc. took the world by storm. For Phil Dormitzer, it’s a reminder of why he was hired at the UK drugmaker: to help return its immunization business to the top after it stumbled during the pandemic.
by james paton, bloomberg
Phil Dormitzer, who left Pfizer to become GSK’s global vaccine research chief, will need to move beyond the Covid shot and deliver some breakthroughs to challenge his former employer and other rivals. The pressure is on as the British company prepares to spin off its consumer unit this month.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Moderna on booster race: May the best data win
For subscribers
.jpg)
.jpg&w=384&q=75)
